Literature DB >> 33947691

ALK Inhibitors in Neuroblastoma: A Sprint from Bench to Bedside.

Johannes H Schulte1,2,3, Angelika Eggert4,2,3.   

Abstract

Activating mutations of the anaplastic lymphoma kinase (ALK) gene were identified in the pediatric tumor neuroblastoma, in 2008. Rapid translation of this finding into targeted neuroblastoma therapy was facilitated by the availability of ALK inhibitors developed for adult malignancies and an efficient preclinical and clinical research program.See related article by Foster et al., p. 3543. ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33947691     DOI： 10.1158/1078-0432.CCR-21-0627

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  2 in total

1.  Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions.

Authors:  Karin Schmelz; Joern Toedling; Matt Huska; Maja C Cwikla; Louisa-Marie Kruetzfeldt; Jutta Proba; Peter F Ambros; Inge M Ambros; Sengül Boral; Marco Lodrini; Celine Y Chen; Martin Burkert; Dennis Guergen; Annabell Szymansky; Kathy Astrahantseff; Annette Kuenkele; Kerstin Haase; Matthias Fischer; Hedwig E Deubzer; Falk Hertwig; Patrick Hundsdoerfer; Anton G Henssen; Roland F Schwarz; Johannes H Schulte; Angelika Eggert
Journal:  Nat Commun       Date:  2021-11-23       Impact factor: 14.919

Review 2.  Anaplastic lymphoma kinase inhibitors and their effect on the kidney.

Authors:  Marco Bonilla; Kenar D Jhaveri; Hassan Izzedine
Journal:  Clin Kidney J       Date:  2022-02-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.